Masimo (NASDAQ: MASI) and Royal Philips (NYSE: PHG; AEX: PHIA),
both global leaders in patient monitoring, announced today that
they have reinforced their partnership, whereby Philips will
integrate additional Masimo measurement technologies into select
IntelliVue® MX-series multi-parameter monitors, to help clinicians
assess cerebral oximetry and ventilation status.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200527005128/en/
Core Masimo noninvasive measurements, such as SET®
Measure-through Motion and Low Perfusion™ pulse oximetry and
advanced rainbow SET® Pulse CO-Oximetry parameters like noninvasive
hemoglobin (SpHb®), have long been available on a wide range of
Philips multi-parameter monitors.
In 2016, Masimo and Philips entered into a multi-year business
partnership involving both companies’ innovations in patient
monitoring and therapy solutions. Now, in 2020, Philips becomes one
of Masimo’s first industry partners to launch additional advanced
Masimo measurements, NomoLine and O3, in their own patient
monitors, sharing Masimo’s expertise in capnography and regional
cerebral oximetry with caregivers and patients around the
world.
NomoLine capnography and O3 regional oximetry measurements are
available now on Philips MX500 and MX550 monitors [1] in select
markets [2] throughout the world, and are also available directly
from Masimo on its Root® Patient Monitoring and Connectivity
Platform and when connected to select Philips patient monitors via
Philips’ IntelliBridge module:
- NomoLine “no-moisture” sampling lines are designed for low-flow
applications and can be used in a variety of clinical scenarios and
care settings, on both intubated and non-intubated patients of all
ages, in both low- and high-humidity applications.
- O3 regional oximetry may help clinicians monitor cerebral
oxygenation in situations in which pulse oximetry alone may not be
fully indicative of the oxygen in the brain.
“As global leader in health technology, we are delighted to
reinforce our partnership with Masimo, bringing their advanced
measurements to our innovative IntelliVue patient monitors, thereby
making them even more versatile,” said Frans van Houten, CEO of
Royal Philips. “Our customers expect integrated solutions to help
them address the quadruple aim of healthcare. The complementary
strengths of Philips and Masimo allow us to offer, reliable
ventilation and regional oximetry solutions, which we expect will
help clinicians deliver even better patient care.”
“Combining our expertise in noninvasive monitoring and signal
processing technologies with Philips’ expertise in integrated
patient monitoring and therapy solutions is a win-win for patients
and clinicians alike,” said Joe Kiani, Founder and CEO of Masimo.
“We are proud that Philips, recognizing our expertise in this
clinical space, has chosen to make our innovative O3 and NomoLine
platforms available to their customers. We look forward to
continuing our partnership with a focus on improving patient
outcomes and reducing the cost of care.”
[1] Pending 510k, not available for sale in the USA
[2] Not for sale in Albania, American Samoa, Bosnia and
Herzegovina, Brazil, Belarus, Canada, China, Columbia, Costa Rica,
Algeria, Egypt (O3 is available for sale), Guam, Hong Kong,
Indonesia, Iran, Japan, Kenya, Cambodia, Korea, Kazakhstan, Sri
Lanka, Morocco (O3 is available for sale), Montenegro, Macedonia,
Northern Mariana Islands, Mexico, Malaysia, Panama, Peru,
Philippines, Puerto Rico, Serbia, Russian Federation, Saudi Arabia,
Singapore, Syrian Arab Republic, Thailand, Turkey, Taiwan, Ukraine,
Venezuela, U.S. Virgin Islands, Vietnam, South Africa.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
enabling better outcomes across the health continuum from healthy
living and prevention, to diagnosis, treatment and home care.
Philips leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions. Headquartered in
the Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2019
sales of EUR 19.5 billion and employs approximately 81,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. Our mission is to improve patient outcomes and reduce
the cost of care. Masimo SET® Measure-through Motion and Low
Perfusion™ pulse oximetry, introduced in 1995, has been shown in
over 100 independent and objective studies to outperform other
pulse oximetry technologies [1]. Masimo SET® has also been shown to
help clinicians reduce severe retinopathy of prematurity in
neonates [2], improve CCHD screening in newborns [3], and, when
used for continuous monitoring with Masimo Patient SafetyNet™ in
post-surgical wards, reduce rapid response team activations, ICU
transfers, and costs [4-6]. Masimo SET® is estimated to be used on
more than 200 million patients in leading hospitals and other
healthcare settings around the world [7], and is the primary pulse
oximetry at 9 of the top 10 hospitals according to the 2019-20 U.S.
News and World Report Best Hospitals Honor Roll [8]. Masimo
continues to refine SET® and in 2018, announced that SpO2 accuracy
on RD SET® sensors during conditions of motion has been
significantly improved, providing clinicians with even greater
confidence that the SpO2 values they rely on accurately reflect a
patient’s physiological status. In 2005, Masimo introduced rainbow®
Pulse CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be
measured invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen
Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7® and
Radius PPG™, portable devices like Rad-67™, fingertip pulse
oximeters like MightySat® Rx, and devices available for use both in
the hospital and at home, such as Rad-97®. Masimo hospital
automation and connectivity solutions are centered around the Iris®
platform, and include Iris Gateway®, Patient SafetyNet, Replica™,
Halo ION™, UniView™, and Masimo SafetyNet™. Additional information
about Masimo and its products may be found at www.masimo.com.
Published clinical studies on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
[1] Published clinical studies on pulse oximetry and the
benefits of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
[2] Castillo A et al. Prevention of Retinopathy of Prematurity
in Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
[3] de-Wahl Granelli A et al. Impact of pulse oximetry screening
on the detection of duct dependent congenital heart disease: a
Swedish prospective screening study in 39,821 newborns. BMJ.
2009;Jan 8;338.
[4] Taenzer AH et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
[5] Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
[6] McGrath SP et al. Surveillance Monitoring Management for
General Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
[7] Estimate: Masimo data on file.
[8]
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements: Masimo
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo NomoLine®, O3®,
SET®, rainbow SET®, and Root®. These forward-looking statements are
based on current expectations about future events affecting us and
are subject to risks and uncertainties, all of which are difficult
to predict and many of which are beyond our control and could cause
our actual results to differ materially and adversely from those
expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including Masimo NomoLine, O3, SET®, rainbow SET®,
and Root, contribute to positive clinical outcomes and patient
safety; risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions and unique
advantages; as well as other factors discussed in the "Risk
Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be obtained
for free at the SEC's website at www.sec.gov. Although we believe
that the expectations reflected in our forward-looking statements
are reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these statements or the "Risk Factors" contained
in our most recent reports filed with the SEC, whether as a result
of new information, future events or otherwise, except as may be
required under the applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200527005128/en/
Steve Klink Philips Global Press Office Tel.: +31 6 10888824
E-mail: steve.klink@philips.com
Evan Lamb Masimo Tel.: +1 949 396 3376 E-mail:
elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2023 to Apr 2024